Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and Reviva ...

About the interviewee: Dr Vanessa dos Reis Ferreira is responsible for working with European patients organisations at Santhera Pharmaceuticals. She has a unique perspective of having been a rare ...

At close: 21 January at 17:30:20 CET ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

At close: 21 January at 3:00:00 pm GMT-5 ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Vanda Pharmaceuticals stock opened at $4.51 on Tuesday. The business’s 50-day simple moving average is $4.81 and its 200-day simple moving average is $5.03. The firm has a market capitalization ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports.